Simbrinza  (U.S.N.L.M.)
Dosing 1 drop tid
Chem Specs brinzolamide 1% / brimonidine 0.2%
Quantities 8ml
Cost 216.82
Class CAI / selective α 2 receptor agonist
Action CAI's slow the formation of bicarbonate with subsequent reduction in sodium and fluid
transport. Brimonidine reduces aqueous production and increases uveoscleral outflow.
Usage Indicated for the reduction of elevated IOP in open-angle glaucoma or ocular hypertension.
First line therapy for patients unable to use PGA's.
Also shown (in Alcon supported study) to be an effective adjunct to PGA therapy.
Contraindications Hypersensitivity to any ingredients in the product.
Warnings Systemic absorption of sulfonamides (Brinzolamide) can lead to severe adverse
reactions, e.g. epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, etc.
Be alert for sensitisation from readministration. Brimonidine may potentiate effects
associated with vascular insufficiency.
Pediatric use Contraindicated in children under the age of 2
Pregnancy Category C.Rabbit maternal toxicity at 120x normal human dose. Slight increase in fetal variations at 20x.
Tachyphylaxis and allergic responses less common with Brimonidine than
Apraclonidine. 0.003% BAK
    N.L.M. DailyMed page for Simbrinza         PDR page for Simbrinza